with standard treatments of tumorous disease. Experimental and clinical data confirming the significance of proteases in a wide range of physiological, pathophysiological, and even therapeutic processes has increased, mostly in recent years. This evidence has been proven by randomized clinical trials, many of which have been double-blinded. Proof of these developments was shown when proteolytic enzymes were approved as medicaments in 1999 by the International Organization for the Categorization of Drugs. The status was changed from the group headed as Digestives (A09A) to the group Anti-inflammatory enzymes (M09AB). This official change on the perspective of pharmacological and therapeutic effects of proteases in the international scientific community can be considered a fundamental step forward in the evolution of this still underused class of pharmacological drugs. Even though use of plant and animal proteases in the treatment of a series of diseases dates back to early history, debates between experimental and clinical camps are ongoing as to the value of exogenously administered proteases and their local and systemic effects. The principal areas of discussion are as follows:
• Mode of application • Allergogenesis after enteral administration • Resorption of proteases in the gastrointestinal tract • Alteration of inflammatory diseases by proteases • Influence of proteases on the primary tumor and its metastases • Influence of proteases on the immune system and immunopathological conditions I n the treatment algorithm for solid tumors, the conundrum presented is not usually about which surgical procedure with adequate lymphadenectomy to perform but rather curing the consequent systemic spread of the tumor and organ metastases. Because of the inherently poor long-term prognosis of such cancers, the majority of these cancers cannot be significantly treated surgically. Conventional chemotherapy offers only limited possibilities to securely restrict or suppress local recurrence of the primary tumor. The same is true in preventing generalization of the tumor. For these reasons, medication with chemopreventive effects has been intensely sought.
Chemoprevention actually represents a tertiary mode of prevention of tumorous diseases. By this, we understand the use of such pharmacological or natural agents that restrict invasive growth by blocking DNA damage (the initiator of carcinogenesis) or the use of a substance that stops or even reverses mutability of precancerous cells and therefore inhibits or defers origination of metastases. 1 Of many years standing, the author's theoretical, experimental, and clinical ambitions have been to better understand the positive observations of a great number of physicians who have described the significant benefits afforded to patients who received proteases concurrently Martin Wald, MD In this monograph, the chemopreventive effects of enterally administered proteases (trypsin, chymotrypsin, and papain) have been documented in a series of animal experimental tumor models. The experimental evidence demonstrates a significant inhibition of growth of both the primary tumor and the metastatic disseminations. Survival in animals treated with proteases is significantly longer than in untreated animals. The results confirm the fundamental correlation between early initiation of therapy and consequent growth of the tumorous disease. Comparable results have been shown in solid tumors in animal models (melanoma and Lewis lung carcinoma) and in human tumors (pancreatic and breast cancers). In this article, details of the known mechanisms of systemic actions of enterally administered proteases are documented and their relationship with cancerogenesis is discussed.
Exogenous Proteases Confer a Significant Chemopreventive Effect in Experimental Tumor Models
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A great number of arguments exist in the scientific literature that attest to the fundamental positive significance of exogenously administered proteases in the treatment of a broad spectrum of diseases, and in the past few years, an increased open-mindedness in specialists from a number of clinics as well as theoretical researchers is evident in the study of this group of medication. However, a number of questions have remained unanswered.
One of the most apparent central discords is the fact that proteases participate in the pathological processes of a number of diseases; they sustain the diseases and, in some cases, even participate in disease progression. This foremost includes inflammatory diseases, but tumorous and degenerative diseases are also involved.
How then can proteases be used in the therapy of those diseases whose pathophysiology they influence, when we know that exogenous administration increases protease levels in blood, and their concentration at the site of pathology is even greater?
It is precisely on the basis of this apparently contradicting question (and to some degree, from a technocratic perspective) that the trend in pharmacotherapy in the past few decades has been to use protease inhibitors-antiproteases-in diseases with proven elevated levels of proteases! In the attempt to be objective, it must be stated that antiproteases were proven to be unhelpful even in the treatment of acute pancreatitis, a disease where, according to our present knowledge, the elevated proteolytic activity of trypsin, chymotrypsin, elastase, and other proteases (or hydrolases, such as lipase and amylase) is pathognomonic to this illness. Antiproteases have been tested solely in experimental models and not clinically in patients with tumorous diseases. In an attempt to enhance the allergic reaction in animal models by premedication with exogenously administered proteases, to the great surprise of all the researchers involved, the exact opposite results were achieved; that is, there was a marked inhibition of the expected allergic reaction (M. Wald, personal communication). The same results were observed even after the administration of bromelain, a phytoprotease, in an ovalbumin-induced murine model of allergic airway disease, where bromelain exerted an anti-inflammatory effect. 2 Free proteases are responsible for the destruction of pulmonary tissue in the etiopathogenesis of pulmonary fibrosis. A paradoxical course of disease, however, is seen in patients with α 1 -antichymotrypsin deficiency. This is associated with a milder damage to the lung tissue. 3 How can this question be answered without betraying the principles of scientific objectivity?
As proteases comprise a vast number of enzymes, it is evident that there are a number of fundamental biological characteristics inherent in their structures that are, to a greater extent, as yet unknown. In all seriousness one must contend that proteins are the basic constituents of all living organisms, archibacteria included, and they participate in capacities of structure, regulation, and signaling activities. Proteases are integral "opponents" of proteins in living organisms, and they alone are capable of breaking proteins down and preparing them for elimination by the body. The disparate function of proteases may be seen, for example, in the hemocoagulation cascade, the process of implantation of the fertilized egg, the various stages of wound healing, or, conversely, in bacterial colonization of wounds. Furthermore, proteases are an integral part of cancerogenesis and metastatic spread.
Nowadays, the main arguments used to denounce the use of proteases in oncology criticize or underline only the tumor-activating effect of proteases (those actions of cancerogenesis and metastatic spread that are produced by tumorous cells). This is due to the fact that all research is directed toward the hypothesis that protease inhibitors only participate according to these present notions of carcinogenesis. These discussions almost exclusively omit the reality that a large number of proteolytic enzymes are composed of a series of subgroups that not only have different effects in the body but whose activation is also exerted by various means. On the other hand, it is necessary to emphasize that proteases certainly have been used for many centuries in various pharmacological forms, but only in the last few years has serious research objectifying their pharmacological and clinical effects been done. This has been studied foremost at the molecular biology level. Since the times of John Beard, a great number of studies confirming the positive effect of peroral proteases conferring a systematic effect in patients with cancerous diseases have been published. For unknown reasons, however, these studies have not been acknowledged by oncologists despite the fact that the treatment involved has a minimal number of unwanted side effects and represents a relatively high cost-benefit value for the patient. So far, no scientific study has been published in the literature that has proven that adjuvant therapy with exogenous proteases has worsened the course of disease in patients with cancer. It is precisely this contradiction between the positive clinical effects of systemically administered proteases and the current skeptical views of the professional research community on the benefits of proteases in tumorous diseases that led the author to search for empirical and clinical experiences to formulate the hypotheses proven in the experimental models. Obviously, one cannot directly consign results from theoretical hypotheses and experimental models to clinical medicine in humans. Despite this, one must unequivocally accept the results of these experiments as general conclusions of biology, with which one may further expound in the future.
Historical Associations
The term biological scalpel (locally applied proteases) is hardly new in modern medicine. References to bloodless necrectomies (ie, local enzymotherapy) can be found in medical literature as early as the beginning of the first millennium. Naturally, different therapeutical forms were available then. The actual biological structure and pharmacological action of the local effect, however, was and is the same.
The physiological function of enzymes was first mentioned in the 18th century. René Antoine Ferchant de Réaumur (1683-1757) and his younger colleague Lazzar Spallanzani demonstrated, on a simple model, that food in the stomach is not only broken down mechanically but also that elements are present in the stomach juice that "dissolve" the meat. Later, Jean Senebier (1742-1809) dressed poorly healing wounds of his patients with this gastric juice, with excellent results. By doing this, he perhaps became one of the first physicians of modern medical history to use proteases for local proteolysis of necrotic tissue. In an attempt at thoroughness, it should be remembered that indigenous tribes in Brazil and India used pineapples and papaya juice (bromelain, papain) in treating superficial wounds. 4, 5 This was done even before modern science isolated the first proteolytic enzymes from plants and animal tissues, and much earlier than the first scientific research was published on the use of proteolytic enzymes in clinical medicine. In much the same way, plant enzymes have been used to heal since primeval times. This was, of course, a purely empirical method of treatment.
The first scientific discourse on fermentation appeared in the 19th century. In 1834, Berzelius documented that thousands of catalytic reactions occur in animals and plants. The catalysts responsible for these reactions, or rather for this fermentation, were later termed by Pasteur as fermenters (fermentation = break down of organic materials with the help of enzymes). In his experiments, Purkyne discovered the existence of trypsin (1836). The term enzyme itself (from the Greek‚ en zýme = present in yeast) was termed by Kühne in 1878. The proteinaceous structure of enzymes was elucidated by Summer in 1926. Urease was artificially produced in the same year, and crystalline trypsin in 1932. Once the structure of individual enzymes and proenzymes were elucidated in the second half of the 20th century (chymotrypsinogen in 1964, trypsinogen in 1966, and papain in 1970), actual usage of the term enzymology began. Enzymes were already being used in industry by this time.
The first purely specific mention of using proteases to treat tumors appeared in the medical literature in 1911, when John Beard, 6 the English scientist, describes in his first published study many years of auspicious experiences with treating malignant tumors using fresh extracts hydrolyzed from the pancreas of piglets and lambs. This was administered to patients intravenously, intramuscularly, or directly into the tumor itself. He noted that tumor growth stopped or, in some cases, even underwent necrosis. In a great number of his 170 patients treated in this manner, survival was prolonged. The antitumorous action of this pancreatic extract was, however, unable to be confirmed when studied by other laboratories, and Beard's work was soon forgotten. The reason for this was quite possibly the fact that, in contrast to the extract used by Beard, his successors used extract stored in cooled environments and therefore the enzymes lost their activity.
In 1925, Freund and Kaminer 7 published their work that described the lytic action of serum from healthy humans on tumorous cells in tissue cultures. The serum from the patients with cancer themselves was inactive. Loss of the cytolytic activity of the serum from cancerous patients was explained by the presence of inhibitors in the blood of patients with tumorous disease. Freund proved this by mixing blood from patients with cancer with that of healthy patients. In a ratio of 1:2, this mixture no longer had a carcinolytic effect. In the 1930s, Max Wolf started to work with Freund. In in vitro experiments, he concluded that it was possible to remove the inhibitor present in blood of patients with neoplasia by the addition of a minimal amount of chymotrypsin or plasmin. 8 Since then, however, the use of proteases in medicine has taken a new direction. A work that can be considered revolutionary was published in 1953; it describes the attenuated development of experimental edema in rats when injected with proteolytic enzymes. A complete series of proteases have been tested (bromelain, papain, trypsin, ficin, elastase), which have confirmed not only antiedematous effects but also the edema-protective actions. Gradually, the fundamental oncological work by John Beard was forgotten, and the pharmacological actions of exogenously administered proteases were directed toward altering the inflammatory reaction. A great problem, however, proved to be the medical dogma that was widespread at the beginning of the 20th century. This declared, that as proteins (and therefore also proteases) were macromolecules, they cannot be resorbed by the gastrointestinal wall, but there must be enzymes present in the intestines that break down the enzymes into smaller fragments, and later into amino acids, which are only capable of being resorbed by the intestines and used by the body. This tenet, which has been disproved only in the last few years, incapacitated serious scientific research and clinical usage of perorally administered proteolytic enzymes for a great many of years. Nowadays, it is evident that this doctrine concerning the nonabsorbability of macromolecules through the intestinal wall is, from a scientific perspective, clearly untenable. The ability of the intestinal wall to absorb macromolecules, proteins included, is the foundation for the physiological reasoning behind peroral immunizations, and even pathophysiological reactions such as food allergies, infections, and poisoning.
It is interesting to note how long scientists, physiologists, and physicians were willing to defend this centuries-old doctrine without questioning the notion of the impermeability of the intestinal endothelium to proteinaceous macromolecules, when volumes of scientific works contradicting this argument already existed in the second half of the 20th century. [9] [10] [11] [12] [13] [14] At this time, rudimentary hypotheses concerning the systemic antiedematous and anti-inflammatory properties of peroral proteolytic enzymes were formulated. 15, 16 The principal mechanism of action was considered to be primarily the depolymerizing effect on fibrin and the inhibiting effect on plasmin activation (more precisely, the catabolism of plasminogen to plasmin with the subsequent destruction of fibrin). This actuality, which is believed to prove the increased permeability of the intercellular space, originated from a series of experimental and clinical studies concerned with the absorption of various materials by tissues in connection with the systemic administration of proteolytic enzymes.
An experiment performed in 1955 confirmed the influence of systemic proteases on increasing the concentration of antibiotics in lymphatic fluid. 17 In 1961, Neubauer 18 clearly demonstrated in experiments the increased efficacy of antibiotics that were administered concomitantly with plant proteases. In 1958, Rapoport 19, 20 described the successful treatment of tuberculous lymphadenitis and tuberculous fistulas using the combination of tuberculostatic drugs with trypsin. In the same period, Thompson et al 21 published similar results endorsing the combination of antibiotic therapy with trypsin for acute urological inflammations. On the basis of the premise of increased permeability of tissues following peroral administration of bromelain, Baker 11 indirectly demonstrated increased permeability of tissues for antibodies in acne vulgaris in his clinical study.
At present, with our deeper understanding of the physiology and pathophysiology of the inflammatory reaction, as well as the dilemmas of cancerogenesis and metastatic spread, and with the knowledge that traditional systemic chemotherapy is unavoidably reaching its limits, alternative methods of treatment are being sought that are based on inhibiting or activation of chemicals that are naturally present in the body (cytokines, growth factors, procoagulant and anticoagulant factors, adhesion molecules, products of oncogenes, gene suppressors, etc). In addition to this, significant discoveries in enzymology have been made, not only from the biochemical perspective but also in clinical usage.
In the event that we begin to consider employing proteases in treating tumorous diseases, we will verge on nearly a half century of discontinued study. With our new knowledge of the systemic action of proteases, the ever increasing quandaries presented, and the limited possibilities of chemotherapy and radiotherapy in oncology, and even, to a relative extent, the risks involved with such treatments, we may rest assured that the direction we are taking is meaningful and correct. It is evident that one must, in the preclinical phase, found experimental hypothesis on precisely defined experimental work of high quality and direct the future clinical work and studies according to the established professional guidelines.
Pharmacological Actions of Enterally Administered Proteases
Proteolytic enzymes (proteases) administered in a mixture for enteral absorption are derived from both animal and plant sources. These are endopeptidases, which hydrolyze peptide bonds at specific locations on protein (peptide) chains, more or less on the basis of specific affinities to the particular amino acid components of these chains.
Trypsin is a pancreatic endopeptidase that cleaves peptide bonds at the carboxyl terminal of amino acids, predominantly those of lysine and arginine. In experimental models, trypsin was acquired from the pancreas of slaughtered pigs by repeated purification and subsequent activation by the trypsinogen proenzyme. It has a molecular weight of 23 to 24 kDa and an average activity of 37.5 FIP-U/mg.
Chymotrypsin is a pancreatic endopeptidase that hydrolyzes peptide bonds. It cleaves peptides at the carboxyl terminal of tyrosine, phenylalanine, and tryptophan. Chymotrypsin was acquired by extraction and chromatographic purification of bovine pancreas, with consequent activation by the chymotrypsinogen proenzyme. The molecular weight of pure chymotrypsin varies between 23 and 24 kDa. Its specific proteolytic activity is, on average, 400 FIP-U/mg.
Papain is a mixture of proteolytic enzymes isolated from the juice of the fruit of the tropical plant Carica papaya. It has a molecular weight between 23 and 27 kDa. It cleaves peptide bonds, especially at the ester bonds of arginine, phenylalanine, and lysine. It has a specific proteolytic activity of 6.5 FIP-U/mg.
The basis for using a combination of proteases in experiments was founded on the assumption that the resulting proteolytic activities of the enzymes are mutually additive. 22 Another reason for combining them is the experimentally proven postulate of the increased resorption of individual proteases by intestinal mucosa when administered together with other proteases. 23 Neither in animal models nor in human patients was toxicity, mutagenicity, carcinogenicity, or teratogenicity described after enteral administration, even at extremely high doses. 24
Resorption of Enzymatically Active Macromolecules and Their Pharmacokinetics
The essential presumption for systemic activity of enterally administered proteases (per os, per rectum) is that they must be absorbed in the enzymatically active form. 25 On absorption, proteolytic enzymes enter the bloodstream and lymphatic circulation, where they are bound to natural antiproteases. The most important of these is α-2-macroglobulin (α-2-M) and α-1-antitrypsin (α-1-AT). 26 The majority of systemic effects of proteases are achieved primarily by this complex of protease and α-2-M. The formation of this complex begins by the hydrolysis of specific peptide bonds in the α-2-M molecule by proteases. This causes a gross change to the structure conformation of the entire α-2-M molecule. The protease is held and hidden in the α-2-M molecule in a way that restricts the majority of its proteolytic activity. Certain substrates with smaller molecules nevertheless may reach its reactive center and be thus cleaved. Antigenic determinants of the protease may be masked by the protease-α-2-M complex, thereby losing their allergenic effect on the body. On the other hand, the interaction between α-2-M and the activated protease (the so-called fast form) induces new properties to its relationship with many physiologically active molecules that are involved in the immune response. [26] [27] [28] Once a part of the protease-α-2-M complex, proteases are transported into the tissues, where they may be released and become active individually for a short time or work for a relatively long time in the "protease-antiprotease" complex. The liver and pancreas clear these complexes, with 90% of them being excreted into the bile and eliminated in the stool. The biological half-life of enzyme elimination after their resorption is relatively long (12-20 hours for trypsin). Biological availability of enzymes from the perspective of systemic action is quite low after enteral administration. This is approximately 1% of the entire dose given. 29 This explains the need to enterally administer proteolytic enzymes in large doses.
General Biological Actions of Proteases After Enteral Administration
Direct proteolytic action-proteolytic serum activity. There are physiological conditions in the plasma that dictate the equilibrium between the body's free proteases and those that are bound to antiproteases (α-2-M, α-1-AT). After enteral absorption of exogenous proteases, there is a shift in this equilibrium. This represents the so-called proteolytic serum activity (PSA). Even α-2-M-bound proteases participate in this activity. These proteases preserve their proteolytic activity ("limited proteolysis"). Proteases in this way participate in the following capacities: in the specific activity, in regulation and degradation of a whole series of factors committed to the inflammatory reaction (eg, the pathway directed at demasking the antigenic epitope), in the specific proteolysis of a number of cytokines, in the degradation of regulatory factors of proteins, in the activation of their receptors. In addition, proteases catabolize proteins damaged by inflammation and facilitate their phagocytosis and elimination by the venous and lymphatic circulation.
There is a clear relationship between the immune response and the PSA level. 30 Activation of the PSA inhibits excessive concentration of serum proteins (ie, fibrinogen and fibrin, the proteins involved in the acute phase of inflammation) as well as the concentration of pathogenic immune complexes, cytokine polymers, and overexpression of adhesion molecules. The PSA works to maintain and renew immunohomeostasis as an ever-present "nonspecific" regulator. The lower the PSA activation the easier it is for immunohomeostasis to become disordered after exogenous or endogenous embarrassment. In experiments on rats, 31 it was shown that the PSA falls in older rats, and therefore, their immune reaction to toxins or cytokines is not physiological. Similarly in humans, the PSA falls not only with advanced age but also in autoimmune diseases or malignancies. 32 Influence on adhesion molecules. During the course of tumorous disease, as well as in states of acute or chronic inflammation, adhesion molecules are expressed on the surfaces of immunocompetent cells, endothelial cells, and even tumor cells. Their expression is initiated by mediators of cellular activation (histamine, thrombin, leukotrienes, tumor necrosis factor-[TNF]-α, interleukin [IL]-1, IL-6, IL-8, and others). The adhesion molecules function, among other actions, by facilitating adhesion of tumor cells, neutrophils, leukocytes, and monocytes to the vascular endothelium. This promotes their extravasation from the vascular wall into the interstitium, which is the deciding mechanism of every metastatic and inflammatory process.
Proteolytic enzymes and their combinations are able to inhibit expression of adhesion molecules on cells either indirectly, by catabolism of inflammatory mediators, or directly. Specific studies in vitro have confirmed their receptivity by important molecules such as CD44, CD45, CD4, CD80, CD62L, CD54, and CD106. [33] [34] [35] [36] [37] Action on local and systemically acting cytokines. Cytokines (eg, TNF-α, transforming growth factor-β [TGF-β], interferon-γ, IL-1, IL-6) participate in a whole series of physiological and pathological reactions in the body that may facilitate development of chronic inflammatory reactions or may even be responsible for the progression of tumorous disease. These include the autocrine cytokine TGF-β, whose overproduction is involved in chronic inflammations, progression of fibrosis, and even the development of a number of immunopathological processes. Cytokines in the blood plasma are bound (in much the same way as proteases) to antiproteases, most notably to α-2-M. 26 The bond between cytokines and antiprotease is itself not quite strong, and thus the cytokine easily regains its activity once this bond breaks. If, however, the cytokine becomes attached to the α-2-M-protease complex, a strong bond is formed, which inactivates the cytokine, and the entire complex (protease-antiprotease-cytokine) is quickly eliminated by the phagocytic cells of the liver and spleen. Proteases accelerate, in this way, the elimination of the pathologically elevated levels of certain cytokines. [38] [39] [40] A similar mechanism of elimination was experimentally proven for immune complexes and the amyloid polymer, which is responsible for the development of Alzheimer's disease. 41 Immunomodulation by increased clearance of immune complexes. Circulating immune complexes (CICs) are composed of antigens of exogenous or endogenous origin and their antibodies. They comprise a significant component of the proinflammatory immune system. CICs may be formed in physiological states, but they are gradually phagocytosed and digested by the cells of the mononuclear phagocytic system. Phagocytes, however, cannot remove these CICs in chronic states or in disorders wherein excess of CIC is formed. The CICs persist in the blood and form greater aggregates that no longer are able to transport through vascular and tissue walls. The deposited CICs result in stimulation of the immune response; they activate the complement system and other mediators of inflammation, as well as the coagulation cascade. Their overabundance also has immunosuppressive actions.
Proteolytic enzymes (mostly papain and bromelain) inhibit the formation of CICs and normalize their clearance. They are even able to catabolize clumps that are found in the circulation and those clumps that are deposited in tissues. 42 For example, in in vitro studies, Kunze et al 43 found that CICs processed by proteases lost their ability to bind C1q and activate the complement cascade. In this way, the vicious circle of CIC formation is interrupted. 44 The action of protease-activated receptors. A relatively recent discovery, which is directly related to the biological activity of proteases, is its influence on the so-called protease-activated receptors (PARs). 45 PARs are ubiquitous receptors that can be found on various cell types and participate in a series of processes responsible for maintaining homeostasis. They are present primarily on normal and neoplastically transformed immunocompetent cells, on the endothelium and muscle cells of large and smaller vessels, on the intestinal epithelium, on the epithelium of glands with both endocrinous and exocrinous secretions, and on keratinocytes, fibroblasts, and other cells. 46 The PARs are composed of 7 transmembranous areas that are activated by the proteolytic digestion of the N-terminal on the extracellular domain. In doing so, the curtailed extracellular area becomes an activated ligand. Activation instigates the transmembranous transmission of the signal to various G-proteins, which then, by genomic change, alter the inflammatory cascade or cell growth.
The PAR also serves to regulate the interchange of material between the vascular lumen and the interstitium under physiological conditions. Activation of its receptors leads to vasodilatation regulated by nitrous oxide and, through this, to improved microcirculation in areas damaged by inflammation or trauma. 47 Transmembranous activation leads to a series of biochemical changes inside the cell. These include, for example, mobilization of calcium ions and consequent secretion of IL-6 and granulocyte macrophage-colony stimulating factor. In cultures of cancer cells from the pancreas (PaCa-2), trypsin and its agonists increased mobilization of calcium, temporarily increased the concentration of I-P 3 , and accelerated translocation of protein kinase C. An attenuated synthesis of DNA was also observed in these cells. In the intestinal epithelium, PAR activation leads to the mobilization of arachidonic acids and consequent secretion of prostaglandins. [48] [49] [50] [51] [52] Through PAR activation, proteases regulate the turnaround of materials between the vascular lumen and the interstitial tissue, thereby contributing to changes of hydrodynamics (altered regulation of the oncotic pressure) and in this way help reduce the inflammatory edema and subsequently improve microcirculation for better removal of accumulated mediators of inflammation and cellular detritus from the focus of inflammation. 53 However, the significance of PARs in antiinflammatory immunity is not yet completely understood.
The influence of exogenous proteases on AGE. Advanced glycation end products (AGEs) originate from nonenzymatic reactions between the ketone or aldehyde group of glucose with the free amino group of proteins, lipids, or amino acids. This induces a chemical modification of protein and lipids, including the low-density lipoprotein (LDL) groups. This modification is the basis for the structural and functional change to the proteins of the plasma and the extracellular matrix. Formation of cross-linking between proteins results in the subsequent thickening of the basal membrane. The end result of AGE-induced modification of lipoproteins (apoprotein B, LDL) is their delayed clearance, which is mediated by normal LDL receptors. The interaction of AGEs and their receptors (RAGEs) and/or binding proteins at the cell surface may induce cellular activation, increased formation of oxygen radicals with the subsequent activation of nuclear κB (NF-κB), and increased synthesis of cytokines, growth factors, and adhesion molecules. In the same way, cellular proliferation or programmed cell death may be induced. This may depend on which type of cell the AGEs react with. The participation of AGEs on the pathogenesis of severe vascular complications in diabetes (nephropathy, retinopathy, neuropathy, and atherosclerosis) and in renal failure can be explained by this method of action, as can certain neurodegenerative diseases (Alzheimer's disease). The process of aging may also be associated with AGE accumulation. 54 The effects of AGEs on the function of endothelium have been very clearly characterized. In in vitro and in vivo experiments, AGEs "extinguish" the effects of nitrous oxide, leading to imperfect vasodilatation. Transendothelial chemotaxis of monocytes is enhanced, secretion of platelet-derived growth factor increases, and expression of certain adhesion molecules (vascular cell adhesion molecule-1 and intercellular adhesion molecule-1) increases. Combined glycation of the extracellular matrix and stimulation of inflammation facilitates the process of endothelial adhesion. 55 The proteases trypsin and bromelain significantly decrease the concentration of AGEs and the products of lipid oxidation, both in vitro and in vivo. After protease administration, a decrease in the number of RAGEs was observed on the surface of cells, along with an increase in their concentration in the intercellular space. First, this lowers the probability of AGE-receptor interactions and at the same time allows for "inactivation" of AGE via the AGE-RAGE soluble complexes. The consequences of decreased levels of AGE are identifiable as lowered concentrations of TGF-β and a lower incidence and subsequent fibrotization or "damage" to the DNA. 56 These findings are also consistent with the notion that because AGE-induced gene damage is mediated by binding to its receptor, trypsin and bromelain inactivate the extracellular domain of this receptor. 57 Increased absorption and boosting of the action of antibiotics and chemotherapeutics. With concomitant administration of proteases with other medications (primarily antibiotics), a heightened serum concentration of these drugs results, resulting in greater utilization by the target tissue. The serum concentration of ampicillin is increased by 25%, trimethoprim by 21%, and tetracycline by 22%. 13, 14, 17, 18, 20, 58, 59 A similar effect has been described in the literature for chemotherapeutic agents, whose measured levels are augmented in tumor cells after concomitant administration of chymotrypsin. 60
The Significance of Enteral Proteases on the Course of Cancerogenesis and Metastasis
Cells that participate in the genesis and progression of tumorous disease communicate with each other via cytokines, adhesion molecules, membranous receptors, and other mediators. Because proteases act, to various degrees, on all these elements, the value of proteases in antitumorous therapy must be considered from multiple perspectives. Proteases may increase the antitumorous immune response at many different levels: in cases involving growth of the primary tumor or metastatic spread, when the primary cellular defenses against gene transformation have failed, and when, for various reasons, even the immune surveillance is deficient, the effect of proteases realized by normalization of immunity becomes vital. They are also important in uncovering tumor cells or deposits and in the proteolysis of the fibrin envelope that is produced by the tumor to evade the body's immune control, among other things. Immunogenicity of the cancer cells increases after fibrinolysis and the immune system may better apply its oncolytic defenses. Furthermore, proteases provoke a manifold increase in activity of a number of cells involved in the antitumorous surveillance of the body. In in vitro experiments, there was a 7-fold increase in the activity of macrophages after 10 minutes in the presence of proteases, and the activity of natural killer cells increased 13-fold. 42 In in vitro and ex vivo experiments, Desser et al [61] [62] [63] showed that in patients who received a combination of proteases perorally, there was a significant increase in the production of TNF-α, IL-1β, and IL-6 by mononuclear cells and an exceptional intensification of the "respiratory burning" in granulocytes. 64 During this phase, granulocytes produce superoxides, which are catabolized to chloride acid and/or hydroxyl radicals. These elements have potent antimicrobial and tumoricidal actions.
Once cells detach from the primary tumor and enter the blood or lymph, modulated expression of adhesion molecules and subsequent activation of the cytokine response (ie, TNF-α and TGF-β) may be significantly increased. The tumor cells survive longer in the circulation, and the immune system has more time to identify and eliminate them. Here also the fibrinolytic effects play an important role in demasking tumor cells. A major role is played by the protease-α-2-macroglobulin complex, which serves to increase the clearance of TGF-β, whose increased concentration provokes a significant tumor growth. From the point of view of oncosurgery, the activation of proinflammatory reactions in the immediate postoperative period or period of adjuvant and neoadjuvant radiotherapy/chemotherapy is also not negligible. As a result of this "therapeutic aggression," a more or less systemic inflammatory reaction in the body ensues, which acts to optimize the conditions for deposition of metastatic cells via endothelial activation, expression of adhesion molecules, activation of the cytokine cascade, and in the procoagulation cascade. At present, there is another substantial argument confirming the advantages of systemically acting proteases in the treatment algorithm for tumorous diseases. This is the aforementioned PAR receptor. The component that activates them (proteases) is capable, through other mediators, of altering intracellular processes, including influencing the growth and differentiation processes. It seems that between the individual PARs there are great differences in their relationship with the tumorous process. Concerning immunity directed against tumors, PARs also improve the rheologic characteristics of body fluids and facilitate transference through the extracellular matrix.
In-house Experimental Studies
Experimental studies usually evoke severe criticism. It is debatable how applicable the conclusions of the experimental work are to clinical medicine. This article has set itself with the task of mainly studying the biological behavior of cancer tissues in vivo under the influence of a precisely defined group of drugs. The truth, however, remains that no experimental model is ideal-it cannot be identical to a specific human disease. The conclusions reached cannot be directly applied to the therapeutic algorithm for humans.
The aim of these groups of experimental works was to find the answer to the following questions: The experimental studies are presented below chronologically, in the order in which they were actually performed. In this way, the gradual development and depth of our perspective on the field of protease use in cancerogenesis has been outlined. Initial experiments have evaluated absolute survival of treated and nontreated animals (control group). The size of the primary tumor and extent of metastatic spread was evaluated. After confirmation of initial results on a large number of animals, we began to concentrate on the relationship between therapeutic success and the time of treatment initiation.
The majority of experiments focused on solid tumors, more specifically, when animal tumors were transplanted into one murine inbred line. Therefore, there is an antigenic match in normal histocompatibility antigens (B16 melanoma, Lewis lung cancer).
In studying the growth of human tumors (breast cancer, pancreatic cancer), genetically immunocompromised mice were selected (nu/nu). Thus, it is obvious that these animals do not possess an immune system identical to humans. Nevertheless, they have been used for a number of decades as the standard model for testing antitumorous medications. Of particular significance are the results from experiments on hematological malignancies-spontaneous lymphoblastic leukemia in laboratory rats. These experiments are not, however, presented in this article. 65 In the later phases of the group of experimental studies presented, the focus was directed to aspects on the molecular biology of proteases on the tumor cell. In all the experiments, animals were housed and fed appropriate measures. The mixture of proteases in the enzyme group was applied per rectum in equal concentrations and at doses of 45 mg/kg body weight/day twice daily (10 mg trypsin + 10 mg chymotrypsin + 25 mg papain). The control group received 0.1 mL of natural saline at the same time and in the same manner as the study group (placebo). For further details on the study, please refer to the original publication. 65
Malignant Melanoma in Mice I
In the first experiment, 66 the aim was to evaluate whether or not proteases have any influence at all on the tumorous disease process. Inbred C 57 Bl 6 mice were used. A suspension of B16 melanoma cells at a concentration of 2 × 10 6 cells was intradermally inoculated into 20 mice. Extirpation of the primary tumor was performed 10 days following inoculation, the mice were divided into 2 groups (10 + 10), and rectal application of either protease mixture or placebo was initiated. This continued until either death of the subject or until the end of the study (100 days). All animals were dissected, and the organs affected by metastatic spread were histologically and immunohistochemically examined. The results of the experiments are summarized in Figure 1 . Whereas all animals in the control group died after an average survival of 24 days, 30% of animals in the study group survived the entire duration of the study without signs of malignancy. Seventy percent of the animals treated died as a result of metastatic invasion, but the average survival length was prolonged by 58.3% (38 days) in comparison with the control group. On the basis of histological and immunochemical examinations, a greater degree of metastatic invasion was observed in the control group compared with the study group. A significant inhibition of metastatic spread and, in relation to this, a greater time of survival after protease administration was confirmed by this experiment.
Malignant Melanoma in Mice II
The goals of this study 67 were to confirm the antimetastatic effects of a mixture of proteolytic enzymes (trypsin, chymotrypsin, and papain) that had been determined in the previous experiment on B16 melanoma in C 57 Bl 6 inbred mice and to evaluate the antiproliferative effect in conjunction with the time of initiation of rectal application of the protease mixture. The densities of CD44, CD54, and CD106 adhesion molecules were evaluated on the surface of melanomatous tumor cells in the primary tumor as well as those on metastases and cells implanted in the peritoneal cavity.
In contradistinction with the previous experiment, a total of 140 mice were used in the study, which were divided into 4 groups: E1 (enzyme = 50 mice) and C1 (control = 20 mice); received a mixture of proteases or placebo rectally 24 hours following transplantation with B16 melanoma cells. E2 (enzyme = 50 mice) and C2 (control = 20 mice); received a mixture of proteases or placebo rectally on the day of primary tumor removal.
Survival of mice and B16 melanoma invasion were evaluated after a 100-day period. All mice were dissected and the organs were histologically examined. The expression of CD44, CD54, and CD106 adhesion molecules were subsequently evaluated on cells of the primary tumor, on cells taken from lung metastases, and on tumor cells present in the abdominal cavity from both control and enzyme groups.
The results ( Figure 2 ) here confirmed those of the previous experiment. Tumor size was remarkably smaller (in mm 3 ) in the E1 group (73.8) when compared with the E2 group (302.4), the C1 group (298.9), and the C2 group (293.8). In addition, the primary tumor hardly grew in 36% of animals in the E1 group. Survival of mice due to B16 melanoma generalization was an average of 27.25 and 28.65 days in the (C1 and C2) control groups, whereas in the enzyme groups (E1 and E2), survival was 72.06 and 53.5 days (Figure 2 ). Although there were no observed changes in the expression of adhesion molecules in the cells taken from metastases when compared with cells from the primary tumor, cells harvested from the peritoneal cavity evinced a decreased expression of CD44 and CD54 in the enzyme group when compared with the control group.
Another noteworthy observation was that even though the average volume of the primary tumor growth was practically identical in groups E2, C1, and C2, the length of survival of animals in the E2 group was almost double that of the control group.
Lewis Lung Cancer
Even in this experimental work, 68 which evaluated the influence of a combination of proteolytic enzymes (trypsin, chymotrypsin, and papain) on the length of survival in C 57 Bl 6 mice after subcutaneous transplantation of Lewis' lung carcinoma, the results were practically identical to those of the malignant melanoma study. From the previous study, it had been ascertained that a mixture of proteases significantly mitigated the metastatic potential and notably increased survival in treated rats in comparison with untreated rats. This depends on the time of treatment initiation. For these reasons, in this final study importance was placed on following the relationship between inoculation of the primary tumor, its removal, and the time of protease treatment initiation. For this reason, in contrast to the previous experiment, we added another study group to the standard design, where protease or placebo was administered during primary tumor growth (this was signified as 6 days after transplantation of the primary tumor).
For this experiment, 40 C 57 Bl 6 inbred mice were intradermally inoculated with 4 × 10 6 cells of murine Lewis lung cancer, and the animals were subsequently divided into 4 groups. The enlarging primary tumor was surgically removed 12 days following inoculation. Application of a mixture of proteases to the study groups was initiated at study days 1 (after tumor inoculation), 6, and 12 and continued until animal death. Placebo administration in the control group was initiated at study day 1 (after tumor inoculation) and continued until animal death. The length of the study was 100 days, after which all surviving animals were euthanized. Dissection and histological examination was performed in all animals, as well as the standard examination of lungs, liver, local recurrence of the primary tumor, and any metastases in the axillary lymph nodes.
Considering that Lewis lung cancer is not as aggressive a tumor as malignant melanoma, the results were even more pronounced (Figure 3 ). Ninety percent of mice in the control group (K) died from metastatic generalization by the 18th day after surgical removal of the primary tumor. One animal died of heart failure with pulmonary edema without signs of tumor dissemination on day 27.
In the enzyme group (A), where rectal application of proteases was initiated on the day of surgical removal of the primary tumor (ie, 12 days after inoculation), 30% of mice died as a result of tumor dissemination. This accounted for an average survival length of 25 days. In the second enzyme study group (B; animals treated 6 days after inoculation of the primary tumor), only 10% of animals died by the 15th day of the experiment as a result of tumor generalization.
In the third enzyme study group (C; enzyme treatment was initiated within 24 hours after inoculation of the primary tumor), no animal died. Furthermore, on dissection and histological examination, there was no case of manifested tumor generalization of the primary tumor.
No mice from the control group survived until the end of the experimental study (100 days). The cause of death in 90% of mice from these groups was tumorous cachexia. The percentages of mice that survived the enzyme study groups at the end of the study period were 60%, 90%, and 100%. Furthermore, no symptoms of tumor generalization were found in mice that survived.
From the combined results of all 3 experiments it is evident that continuous rectal application of a mixture of proteases (trypsin, chymotrypsin, and papain) in C 57 Bl 6 inbred mice resulted in a significant antiproliferative effect. This was evinced as a decrease in the local tumor progression, as well as the antimetastatic potential expressed as a profound difference in the length of survival in mice treated with an admixture of proteases. This effect was also substantiated by the change in density of adhesion molecules present on the metastatic cells that were influenced by the mixture of proteases.
Human Pancreatic Cancer
The goal of this experimental work 69 was to ascertain to what extent, if any, an admixture of proteases (trypsin, chymotrypsin, and papain) given rectally is capable of altering the growth of human pancreatic adenocarcinoma transplanted in nu/nu CD1 mice. Cell blocks of adenocarcinoma of size 3 × 3 mm were subcutaneously transplanted into the right haunches of 20 nu/nu mice. Tumor growth was evinced in 18 mice, and once the tumor volume reached 50 to 75 mm 3 , therapy was initiated for a length of 40 days. The composition of the protease mixture and the method of application were identical with those of the previous experiments. In the enzyme study group (n = 9 mice), a 0.9-mg solution of proteases were administered rectally, whereas the control group (n = 9 mice) received an equal volume of normal saline twice daily rectally. During the course of the study, the size of the tumor was measured twice a week. At the same time, the mice were measured twice weekly. At the conclusion of the study (this amounted to the 41st day), the mice were euthanized and the tumors were removed, examined, and histological inspection performed.
The results of this experiment confirmed that growth of pancreatic tumors in the enzyme group was slower than in the control group (Figure 4) . Moreover, the size of the tumor was 52.4% that of the control group (100%) at the 30th day (ie, the enzyme group had a 47.6% smaller tumor growth). The experiment results showed a slowed growth of the human pancreatic cancer in the enzyme group compared with growth in the control group. The average weight of the tumor in the study group was 0.220 g on the 41st day of the study, whereas the weight was 0.263 g (100%) in the control group. Repeated rectal administration of the protease mixture had no influence on the body weight of the animals studied. Because all animals had the same weight at the end of the study, it is evident that there was greater cachectization in the untreated animals, because the tumor mass must be added to their absolute weight gain. This accounted for a 20% increase in weight in comparison with tumors in the study group.
Human Breast Cancer
The goal of this experiment 70 was to ascertain the influence of a mixture of proteases on the growth of human breast cancer (MDA-MB-231) after implantation into 20 nu/nu CD1 mice. Tumor growth occurred in 17 mice. In 12 of these, the tumor grew to a size of 100 to 120 mm 3 , and these mice were separated into an enzyme study group (n = 6 mice) and a control group (n = 6 mice). Rectal administration of either an admixture of protease or placebo was initiated for a period of 30 days. The mice Although no mice from the control group (K) survived until the end of the study period, and in 90% the cause of death was tumorous cachexia, in the enzyme groups the percentages of survival were 60% (A), 90% (B), and 100% (C). Signs of generalization of the primary tumor were absent in mice from all study groups.
were then euthanized, and the tumors were removed and weighed. One tumor block was studied by the following methods: histological examination (hematoxylin-eosin stain for detection of necrosis), immunohistochemistry (hormonal receptors, p53, c-erb/B2, KI 67, bcl-2, CD34), and expression of adhesion molecules on the FACS. Another tumor block was sent for p53 protein analysis by Western blot. The results showed a significant reduction in cancer growth in the study group, which, 30 days following implantation, reached a volume of only half that of tumors observed in the control group ( Figure 5 ).
In the enzyme group, the levels of c-erb/B2 were 15% lower, the levels of KI 67 were 10% lower, and the volume of necroses were 32% lower when compared with the control group. Immunohistochemical examination, in conjunction with Western blot analysis, showed a 50% reduction in levels of p53 protein in the enzyme group when compared with the control group.
Tumor growth inhibition in the enzyme group may be directly related to the resulting suppression of specific biological characteristics of tumors. A markedly smaller volume of tumor necrosis in the treated group is apparent, as is a reduction in the signs of proliferation and levels of c-erb/B2 oncogenes. Accordingly, a directly proportional reduction in levels of mutated p53 protein gene may be explained by inhibition of tumor growth. The wild type of this suppressor gene functions in cases of cellular mutation that lead to disorders of differentiation through cell division and repair of genomic mutations. In addition, failure of these cellular selfreparative processes activates cell apoptosis. Increased contribution of apoptosis on the inhibition of tumor growth was however not proven.
Conclusion and Discussion
The use of specific proteases in the treatment of inflammatory diseases is widely accepted nowadays. The pharmacological action has been validated by a number of in vivo and in vitro experimental studies as well as clinical trials. Such extensive consensus has, however, not been reached in oncology for the use of selected proteases as adjuvant antitumorous therapy. To provide a justification for the use of selected proteases in oncologic patients, we performed a number of experimental studies in vitro, which confirmed the pharmacological intervention of proteases at a molecular level on the immune reaction, as well as in vivo experimental studies, which proved their antiproliferative and antimetastatic actions. In addition, clinical experiences have been published, of which perhaps the most comprehensive and most conclusive is the work of Sakalova et al. [71] [72] [73] However, controversial data still exist that not only allege the tumor-stimulating actions of The results of the experiment confirmed a slower growth of pancreatic carcinoma in the enzyme group when compared with the control group. In addition, at the 30th day of the study, the study group had a comparative weight of 52.4% (or a 47.6% smaller tumor) when compared with that of the control group (100%).
proteases (metaloprotease) and also acclaim the antitumorous effects (certain cysteine and serine proteases). The presented selection of experimental studies set out to answer certain questions concerning the influence of a rectally administered mixture of proteases (trypsin, chymotrypsin, and papain) on the tumorous process. The conclusions may be summarized as follows:
In all the experiments presented, there is unanimous proof of the inhibition of tumor growth of animals treated with an admixture of proteases in comparison with animals in the control group. This is not only evident in animal tumors (melanoma, Lewis lung cancer) but also in human tumors implanted into immunocompromised mice (breast and pancreatic cancer). In animal tumors that spontaneously metastasize, the experiments concluded a significant reduction in the metastatic invasion of the primary tumor. Both these actualities were demonstrated primarily through a prolonged survival in the enzyme group when compared with the control group. The significance of when to initiate treatment from time of tumor transplantation is derived from our experiments with Lewis lung cancer and melanoma II. It is surprising to note the extent of growth inhibition of the primary tumor and percentages of animals surviving without metastases based on how early treatment is initiated. Undeniably, the fact remains that in 36% of animals treated immediately after tumor implantation (melanoma), the primary tumor was not identified at all by histological examination of the site of original implantation after completion of the study. The experiments succeeded in showing how proteases given systemically confer certain molecular biological changes that take place on the surface of cancer cells. The fundamental change that must be considered as preeminent is the reduction in expression of CD44 and CD54 adhesion molecules. With further trials, it will be necessary to demonstrate changes to the p53 suppressor genes and the c-erb/B2 oncogenes. The requirements for fulfilling the definition of chemopreventive agent have been met. On the basis of results from the aforementioned experimental studies, it may be concluded that a mixture of proteases (trypsin, chymotrypsin, and papain) had a significant chemopreventive effect in all experiments. The chemopreventive effect was directly dependent on the interval between initiation of protease administration and transplantation of the primary tumor.
These results may be explained by the nonspecific increase in cytotoxicity of NK cells as well as elimination of certain paracrine secretions of cytokines, especially TGF-β, which is considered an immunosuppressive agent. The antimetastatic effect is often attributed to the ability of certain proteases to alter expression of a number of adhesion molecules on the surface of tumor cells. Earlier in vitro studies have shown the effect of proteases on the density of adhesion molecules. A reduction in the number of CD44 molecules on the surface of cancer cells via proteases or, for example, specific blockade of monoclonal antibodies lead to diminished adhesion of these cells onto the endothelium of vessels in the target organs. Despite the fact that the basic mechanism of protease action in relationship with expression of adhesion molecules may be explained by direct proteolytic splitting of signal molecules on cell surfaces, the actual mechanism may be realized even through indirect mechanisms.
Receptors that can be activated by protease 2 (PAR2) are powerful mediators of particular cell signal mechanisms.
It is supposed that PAR2 may play an inhibitory role in the regulation of cancer growth. It may be assumed that the influence of a greater proteolytic activity of the blood and interstitial tissues is of importance to tumorous cells present in the circulation and on cells that have not yet aggregated into gross solid formations with "tight" intercellular and stromal adhesions. This presumption is derived from actual data confirming that proteases have a preventive, antitumorous effect on tumor cells implanted into the skin. This was observed in the group of animals that received proteases 24 hours after melanoma implantation: 36% of primary tumors did not grow at all, and the remaining were considerably smaller than tumors from the other groups. It is necessary to demonstrate the conceivable effect of proteolytic activity on distant micrometastases. Nevertheless, from the observed trends of animal deaths in the enzyme and control groups, it may be expected that even growth of distant metastases that have already invaded may be restricted.
From the aforementioned data, it is apparent that physiological serum activity of certain proteases is essential to many intercellular regulatory mechanisms, and this even despite the fact that not all roles have been satisfactorily elucidated. The presence of a number of them in the blood plasma and on cellular elements is still considered an artificial or even pathological finding. Nevertheless, a primary or secondary imbalance in their serum activity (in the sense of reduction) is evidently a result of a disorder in physiological mechanisms of inflammation and antitumorous immunity. This may be caused by either insufficient production or, conversely, through their overproduction by excesses of specific protease inhibitors seen in chronic inflammations or in malignant tumors.
The effect of proteases on dendritic cells (DCs), which are the most potent antigen-presenting cells of the immune system, has so far been overlooked by the scientific community. 74 Serine proteases acting via proteaseactivated receptor-2 (PAR-2) stimulates development of DC from bone marrow progenitor cells cultured in granulocyte-macrophage colony-stimulating factor and IL-4. DCs fail to develop in bone marrow cultures treated with soy bean trypsin inhibitor, a serine protease inhibitor, but this inhibition is overcome by a PAR-2 peptide agonist. 75 In the past decade, oncosurgery has concentrated efforts primarily on the perfection of surgical techniques directed at removing the primary tumor (R0 resection) and extensive lymphadenectomy. In all seriousness, one must, however, realize that this refinement applies primarily to the macroscopic level (or possibly even the microscopic level). Cancer is, from a certain instant, a systemic disease, and therefore, any thorough procedure at a local level is unable to change prognosis.
The perioperative period is a therapeutically "shrouded" period, specifically from the perspective of whether or not the possible systemic progression of the tumorous disease can be influenced. Moreover, it is a period of more or less immunosuppression, coagulopathy, and endothelial activation. Advantageous perioperative and long-term postoperative chemoprevention using a combination of proteases could possibly significantly alter future prognosis, particularly by influencing the tendency for early metastases or by exerting their actions on the remnant tumor. Such scientific ambitions may, however, only be realized in cooperation with economically sound partners and under the auspices of multinational, multifocal, long-term clinical studies. These are essential prerequisites for supplementing the clinical experiences of the therapeutic use of selected proteases in patients with malignancies.
